GLP-1 Science
What Is a GLP-1 Receptor Agonist? A Simple Explanation
GLP-1 receptor agonists are drugs that mimic the fullness hormone GLP-1. Ozempic, Wegovy, and Mounjaro are all in this c...
The honest answer is that tirzepatide produces greater average weight loss than semaglutide. The SURMOUNT-1 trial showed 20.9% average body weight loss with tirzepatide 15 mg over 72 weeks, compared to 14.9% with semaglutide 2.4 mg in the STEP 1 trial. That is a meaningful difference.
But the two drugs are not the same type of medication, the comparison is indirect, and availability varies significantly by country. Understanding what drives the difference matters more than simply picking the "better" number.
What Each Drug Is
Semaglutide is a GLP-1 receptor agonist. It activates one receptor — the GLP-1 receptor — producing the appetite suppression, gastric slowing, and insulin secretion improvements that drive weight loss.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). This second target adds an additional pathway for insulin secretion enhancement and fat metabolism.
The GIP receptor activation is the primary reason tirzepatide produces greater weight loss. GIP enhances the GLP-1 effect rather than replacing it, creating a synergistic response that neither receptor produces alone at the same magnitude.
What the Clinical Trials Show
The SURMOUNT-1 trial tested tirzepatide at 5 mg, 10 mg, and 15 mg weekly:
- 5 mg: 15% average weight loss
- 10 mg: 19.5% average weight loss
- 15 mg: 20.9% average weight loss
The STEP 1 trial tested semaglutide at 2.4 mg: 14.9% average weight loss.
A direct head-to-head trial (SURPASS-2) comparing the two drugs for diabetes management showed tirzepatide produced greater weight loss at all doses compared to semaglutide 1 mg. A direct obesity comparison at maximum doses has not yet been published.
Side Effect Differences
Both drugs produce similar GI side effects — nausea, constipation, and reduced appetite. Tirzepatide at 5 mg produces nausea rates comparable to semaglutide at 1 mg. At maximum doses, both produce similar tolerability profiles.
One potential advantage of tirzepatide's GIP component: GIP may reduce the nausea that GLP-1 receptor activation causes in some patients. Several patients who switched from semaglutide to tirzepatide reported improved tolerability.
Availability and Cost
Semaglutide (Ozempic, Wegovy, Rybelsus) is available in more countries and has been on the market longer. Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) received FDA approval in 2022 and 2023 respectively and is still expanding its market presence.
Neither semaglutide nor tirzepatide is officially registered with DRAP in Pakistan. For Pakistani patients, this comparison is largely academic.
The Pakistan Reality
Neither drug is accessible in Pakistan through official channels. METASLIM provides GLP-1 pathway support — the component both drugs share — through sublingual drops. It is DRAP-registered, available nationwide, and physician-guided. While it does not target the GIP receptor that gives tirzepatide its additional potency, it provides access to the core GLP-1 mechanism that both drugs engage.